share_log

Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina

Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina

Heron Therapeutics宣布公司总部迁址至北卡罗来纳州的凯里
PR Newswire ·  12/24 05:05

SAN DIEGO, Dec. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, announced today the relocation of the Company's headquarters from San Diego, California to Cary, North Carolina, effective January 1, 2025. A majority of Heron's Management Team and corporate employees work from the Cary office, which is near the Research Triangle Park ("RTP"), one of the most prominent high-tech research and development parks in the United States. The growing biotech community in Cary and its surrounding areas provides ample space for growth and expansion.

圣地亚哥,2024年12月23日 /PRNewswire/ -- Heron Therapeutics, Inc. (纳斯达克: HRTX)("Heron"或"公司"),是一家商业阶段的生物技术公司,今天宣布从加利福尼亚州圣地亚哥迁至北卡罗来纳州凯里,迁移将于2025年1月1日生效。Heron的大多数管理团队和企业员工在凯里办公室工作,该办公室位于美国最著名的高科技研发园区之一——研究三角园区("RTP")附近。凯里及其周边地区不断增长的生物技术社区为公司的增长和扩展提供了充足的空间。

"We are excited to move our headquarters to Cary, North Carolina, which represents a significant milestone in Heron's journey," said Craig Collard, Chief Executive Officer of Heron. "This move will not only strengthen our ability to support our employees by centralizing our operations and resources, but also positions us in an excellent location from which we can continue making strategic partnerships as we growing our existing portfolio focused on improving the lives of patients in the acute and oncology care settings. This is an exciting chapter for Heron, and we look forward to the continued success and partnerships that lie ahead."

“我们很高兴将总部搬到北卡罗来纳州凯里,这标志着Heron旅程中的一个重要里程碑,”首席执行官Craig Collard表示。 “这次搬迁不仅将通过集中我们的运营和资源来增强我们支持员工的能力,同时也将我们置于一个出色的地点,从中我们可以继续建立战略合作伙伴关系,发展我们的现有投资组合,专注于改善急性和肿瘤护理患者的生活。这是Heron一个激动人心的篇章,我们期待着未来的持续成功和合作伙伴关系。”

The new address for Heron's corporate headquarters is 100 Regency Forest Drive, Suite 300, Cary, NC 27518.

Heron公司总部的新地址是北卡罗来纳州凯里100 Regency Forest Drive,Suite 300,邮政编码27518。

About Heron Therapeutics, Inc.

关于Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit .

Heron Therapeutics, Inc.是一家商业阶段的生物技术公司,专注于通过开发和商业化治疗创新来改善患者的生活,这些创新改善了医疗保健。我们的爱文思控股科学、专利技术和创新的药物发现与开发方法使我们能够创建和商业化一系列旨在提升急性护理和肿瘤患者标准护理的产品。欲了解更多信息,请访问。

Forward-looking Statements

前瞻性声明

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Therefore, you should not place undue reliance on forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

本新闻稿包含1995年《私人证券诉讼改革法案》所定义的“前瞻性陈述”。Heron警告读者,前瞻性陈述基于管理层截至本新闻稿日期的预期和假设,并受到某些风险和不确定性的影响,这可能导致实际结果与预期结果存在重大差异。因此,您不应过分依赖前瞻性陈述。可能导致实际结果与前瞻性陈述中的结果存在重大差异的重要因素已在我们最新的10-K表格年度报告和任何后续的10-Q表格季度报告以及我们向证券交易委员会提交的其他报告中列出,包括在“风险因素”标题下。前瞻性陈述反映了我们在其声明日期的分析,Heron不承担在法律要求的情况下更新或修订这些陈述的义务。

Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
[email protected]
858-251-4400

投资者关系和媒体联系:
伊拉·杜阿尔特
执行副总裁,首席财务官
Heron Therapeutics, Inc.
[email protected]
858-251-4400

SOURCE Heron Therapeutics, Inc.

来源:Heron Therapeutics, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想让贵公司的资讯在PRNEWSWIRE.COM上特色展示吗?

440k+
440k+

Newsrooms &
新闻编辑室和

Influencers
意见领袖
9k+
9k+

Digital Media
数字媒体

Outlets
Outlets
270k+
270k+

Journalists
记者

Opted In
已选择加入
GET STARTED
开始
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发